ResApp Receives Final Design Files for Handheld and Wearable Devices

Brisbane, Australia, 6th May 2020 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that it has received a set of final design files, reports and supporting documents for the handheld and wearable devices under development by Avanti Med Limited and OSI Electronics.

The Android™-based, ruggedized handheld device is a low-cost option for using ResApp's respiratory disease diagnosis apps in specific in-person clinical environments. The wearable monitor provides an easily worn, unobtrusive platform for up to three days of continuous monitoring of patients with chronic respiratory disease.

Clinical, electrical and usability evaluation is underway, and the results of which will be combined with the design files to form the CE Mark Technical File. CE Mark approval is on target to be achieved in the first half of this calendar year.

The receipt of design files of both devices satisfies the second of three milestones under the device development agreement (ASX: 29 May 2019). Accordingly, ResApp will make a payment of AU$500,000 for each device and has elected to pay in shares. A total of 9,090,909 shares will be issued at a deemed price of $0.11 (calculated using 80% of the volume-weighted average price of shares in the 30 days preceding the satisfaction of the milestone). The shares will be issued under the company's 15% placement capacity.

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically-validated products include ResAppDx-EU, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.

ResApp Health Limited ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane QLD 4000 Australia
T +61 7 3724 0035 **E** info@resapphealth.com.au **W** www.resapphealth.com.au

Contacts for ResApp Health

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.